PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'R&D Department, Promega Corporation, Madison, WI, USA. juliano.alves@promega.com.\', \'R&D Department, Promega Corporation, Madison, WI, USA.\', \'Laboratório de Virologia Molecular, Departamento de Genética, Instituto de Biologia, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.\', \'Promega Biotecnologia Do Brasil, São Paulo, Brazil.\', \'Departamento de Doenças Infecciosas E Parasitárias, Faculdade de Medicina, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.\', \'Instituto de Biofísica Carlos Chagas Filho, Universidade Federal Do Rio de Janeiro, Rio de Janeiro, Brazil.\', \'Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.\', \'R&D Department, Promega Corporation, Madison, WI, USA. hicham.zegzouti@promega.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41598-021-97330-3
?:doi
?:hasPublicationType
?:journal
  • Scientific reports
is ?:pmid of
?:pmid
?:pmid
  • 34531417
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.533
?:rankingScore_hIndex
  • 122
is ?:relation_isRelatedTo_publication of
?:title
  • A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all